Journal of Skin Cancer最新文献_第8页

Dual S-100-AE1/3 Immunohistochemistry to Detect Perineural Invasion in Nonmelanoma Skin Cancers. 双S-100-AE1/3免疫组化检测非黑色素瘤皮肤癌的神经周围浸润。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-18 DOI: 10.1155/2015/620235

Alma C Berlingeri-Ramos, Claire J Detweiler, Richard F Wagner, Brent C Kelly

{"title":"Dual S-100-AE1/3 Immunohistochemistry to Detect Perineural Invasion in Nonmelanoma Skin Cancers.","authors":"Alma C Berlingeri-Ramos, Claire J Detweiler, Richard F Wagner, Brent C Kelly","doi":"10.1155/2015/620235","DOIUrl":"https://doi.org/10.1155/2015/620235","url":null,"abstract":"Background. Perineural invasion (PNI) is an adverse prognostic histologic finding and increases the risk of local recurrence and metastasis. Objective. We aimed to determine if dual immunohistochemical (IHC) staining with S-100 and AE1/3 would increase the detection of PNI on nonmelanoma skin cancers (NMSCs). Methods. We collected 45 specimens of NMSCs in which there was clinical suspicion for PNI. Two dermatopathologists independently reviewed the tumors for the unequivocal presence of PNI. Results. Unequivocal PNI was present on 10 of the 45 tumors by H&E staining and on 15 of the 45 tumors by IHC staining. Large nerves (>0.1 mm) were involved in 3 of 10 H&E-stained cases and 3 of 15 IHC-stained cases, with 2 of the 4 cases demonstrating large nerve involvement with both staining methods. Of the 8 cases of PNI detected only on IHC, 7 were small nerves (≤0.1 mm). Limitations. All cases were selected because they were clinically suspicious for PNI, and this may be considered selection bias. Conclusions. PNI detection may be increased using dual S-100 and AE1/3 staining, but the majority of additional cases detected were small nerves. The clinical significance, given the small size of the involved nerves, is unclear. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/620235","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33041995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study. 伊朗人群蕈样真菌病:流行病学和临床病理学研究。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-01-28 DOI: 10.1155/2015/306543

Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi

{"title":"Mycosis fungoides in Iranian population: an epidemiological and clinicopathological study.","authors":"Farahnaz Fatemi Naeini, Bahareh Abtahi-Naeini, Hamidreza Sadeghiyan, Mohammad Ali Nilforoushzadeh, Jamshid Najafian, Mohsen Pourazizi","doi":"10.1155/2015/306543","DOIUrl":"https://doi.org/10.1155/2015/306543","url":null,"abstract":"Background. Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma. Extensive studies on Iranian MF patients are absent. The present study aimed to produce updated clinical information on Iranian MF patients. Methods. This was a retrospective, descriptive, single-center study, including all cases of MF seen in the Department of Dermatology, University Hospital of Isfahan, Iran, between 2003 and 2013. Data systematically recorded for each patient included clinical, biological, histological, and molecular findings. Results. Eighty-six patients with clinical and histologic diagnosis of MF were included in the study. Thirty-nine patients (45.3%) were male. Female predominance was observed in patients (male : female ratio is 1 : 1.2). Patients were between 7 and 84 years of age (median: 41). The interval from disease onset to diagnosis ranged from 0 to 55 years (median: 1 year). Eighteen cases (20.9%) had unusual variants of MF. The most common types included hypopigmented and poikilodermatous MF. Childhood cases of MF constituted 5.8% (5/86) of all patients. The early stages were seen in 82 cases (95.34%). Conclusion. The major differences in epidemiologic characteristics of MF in Iran are the lack of male predominance and the lower age of patients at the time of diagnosis. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/306543","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33065031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire. 皮肤癌患者的合并症评估:一项比较医学访谈与患者报告问卷的初步研究

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-09 DOI: 10.1155/2015/953479

Erica H Lee, Rajiv I Nijhawan, Kishwer S Nehal, Stephen W Dusza, Amanda Levine, Amanda Hill, Christopher A Barker

{"title":"Comorbidity Assessment in Skin Cancer Patients: A Pilot Study Comparing Medical Interview with a Patient-Reported Questionnaire.","authors":"Erica H Lee, Rajiv I Nijhawan, Kishwer S Nehal, Stephen W Dusza, Amanda Levine, Amanda Hill, Christopher A Barker","doi":"10.1155/2015/953479","DOIUrl":"https://doi.org/10.1155/2015/953479","url":null,"abstract":"Background. Comorbidities are conditions that occur simultaneously but independently of another disorder. Among skin cancer patients, comorbidities are common and may influence management. Objective. We compared comorbidity assessment by traditional medical interview (MI) and by standardized patient-reported questionnaire based on the Adult Comorbidity Evaluation-27 (ACE-27). Methods. Between September 2011 and October 2013, skin cancer patients underwent prospective comorbidity assessment by a Mohs surgeon (MI) and a radiation oncologist (using a standardized patient-reported questionnaire based on the ACE-27, the PRACE-27). Comorbidities were identified and graded according to the ACE-27 and compared for agreement. Results. Forty-four patients were evaluated. MI and PRACE-27 identified comorbidities in 79.5% and 88.6% (p = 0.12) of patients, respectively. Among 27 comorbid ailments, the MI identified 9.9% as being present, while the PRACE-27 identified 12.5%. When there were discordant observations, PRACE-27 was more likely than MI to identify the comorbidity (OR = 5.4, 95% CI = 2.4-14.4, p < 0.001). Overall comorbidity scores were moderate or severe in 43.2% (MI) versus 59.1% (PRACE-27) (p = 0.016). Limitations. Small sample size from a single institution. Conclusion. Comorbidities are common in skin cancer patients, and a standardized questionnaire may better identify and grade them. More accurate comorbidity assessments may help guide skin cancer management. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/953479","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34294397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Oculocutaneous Albinism and Squamous Cell Carcinoma of the Skin of the Head and Neck in Sub-Saharan Africa. 撒哈拉以南非洲地区头颈部皮肤白化病和鳞状细胞癌。

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-08-12 DOI: 10.1155/2015/167847

P T Lekalakala, R A G Khammissa, B Kramer, O A Ayo-Yusuf, J Lemmer, L Feller

引用次数: 50

Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. 靶向治疗与达卡巴嗪治疗BRAF(V600E)转移性黑色素瘤的比较:成本-效果分析

IF 1.1

Journal of Skin Cancer Pub Date : 2015-01-01 Epub Date: 2015-06-10 DOI: 10.1155/2015/505302

Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson

{"title":"Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis.","authors":"Vanessa Shih, Renske M Ten Ham, Christine T Bui, Dan N Tran, Jie Ting, Leslie Wilson","doi":"10.1155/2015/505302","DOIUrl":"https://doi.org/10.1155/2015/505302","url":null,"abstract":"Purpose. Two BRAF(V600E) targeted therapies, dabrafenib and vemurafenib, have received US approval for treatment of metastatic melanoma in BRAF(V600E) patients, a mutation that affects ~50% of patients. We evaluated the cost-effectiveness of BRAF inhibitors and traditional chemotherapy for treatment of metastatic melanoma. Methods. A Markov model was developed using a societal perspective. Transition probabilities were derived from two Phase III registration trials comparing each BRAF inhibitor against dacarbazine. Costs were obtained from literature, national databases, and Medicare fee schedules. Utilities were obtained from published literature. Deterministic and probabilistic sensitivity analyses were run to test the impact of uncertainties. Results. The incremental cost-effectiveness ratio of dabrafenib was $149,035/QALY compared to dacarbazine. Vemurafenib was dominated by dabrafenib. Probabilistic sensitivity analysis showed that, at a willingness-to-pay (WTP) threshold of ≤$100,000/QALY, dacarbazine was the optimal treatment in ~85% of simulations. At a WTP threshold of ≥$150,000/QALY, dabrafenib was the optimal treatment. Conclusion. Compared with dacarbazine, dabrafenib and vemurafenib were not cost-effective at a willingness-to-pay threshold of $100,000/QALY. Dabrafenib is more efficient compared to vemurafenib. With few treatment options, dabrafenib is an option for qualifying patients if the overall cost of dabrafenib is reduced to $30,000-$31,000 or a WTP threshold of ≥$150,000/QALY is considered. More comparative data is needed. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/505302","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34283005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. 黑色素瘤抑制活性蛋白在局部皮肤恶性黑色素瘤中的预后价值。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-06-22 DOI: 10.1155/2014/843214

Angela Sandru, Eugenia Panaitescu, Silviu Voinea, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru

{"title":"Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma.","authors":"Angela Sandru, Eugenia Panaitescu, Silviu Voinea, Madalina Bolovan, Adina Stanciu, Sabin Cinca, Alexandru Blidaru","doi":"10.1155/2014/843214","DOIUrl":"https://doi.org/10.1155/2014/843214","url":null,"abstract":"Background. Cutaneous malignant melanoma (CMM) is a heterogeneous disease, acknowledged for its lack of predictability regarding clinical evolution. In order to appreciate a patient's individual prognosis, an attempt is made to find new tumor markers that parallel the disease progression. Objective. To identify if melanoma inhibitory activity (MIA) protein could represent a tool for selecting high risk early stages melanoma patients. Method. Between 2008 and 2013, 155 patients with CMM were treated in our clinic. 84 of them were classified into stages I and II, according to TNM 2009. MIA serum concentration was measured in all patients and 50 healthy donors. A cut-off value of 9.4 ng/ml was established using the ROC curve. Results. All patients were followed up by periodic investigations every 6 months. We have noticed that 66% of patients with MIA serum values at diagnosis greater than 9.4 ng/mL have relapsed, while only 5% of patients with MIA serum concentration below the estimated threshold, recurred during the follow-up period (P = 0.000). The death risk was 12 times higher in pathological MIA group of patients (P = 0.0001). Conclusions. Our data suggest that MIA is an independent prognostic factor for patients with localized CMM. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/843214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32520027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Treatment patterns in patients with metastatic melanoma: a retrospective analysis. 转移性黑色素瘤患者的治疗模式:回顾性分析。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-05-05 DOI: 10.1155/2014/371326

Zhongyun Zhao, Song Wang, Beth L Barber

{"title":"Treatment patterns in patients with metastatic melanoma: a retrospective analysis.","authors":"Zhongyun Zhao, Song Wang, Beth L Barber","doi":"10.1155/2014/371326","DOIUrl":"https://doi.org/10.1155/2014/371326","url":null,"abstract":"Objective. To describe treatment patterns and factors influencing treatment in a real-world setting of US patients with metastatic melanoma (MM). Methods. This was a retrospective claims-based study among patients with MM diagnosed between 2005 and 2010 identified from MarketScan databases. Results. Of 2546 MM patients, 66.8% received surgery, 44.7% received radiation, 38.7% received systemic therapies, and 17.7% received all modalities. Patients with lung, brain, liver, or bone metastases were less likely to undergo surgery (all P < 0.0001); patients with lung (P = 0.04), brain (P < 0.001), or liver metastases (P = 0.03) were more likely to receive systemic therapies; patients with brain (P < 0.0001) or bone metastases (P < 0.0001) were more likely to receive radiation therapy. Oncologists were more likely to recommend systemic therapy (P < 0.0001) or radiation (P < 0.0001), while dermatologists were more likely to recommend surgery (P = 0.002). Monotherapy was the dominant systemic therapy (82.4% patients as first-line). Conclusions. Only 39% of MM patients received systemic therapies, perhaps reflecting efficacy and safety limitations of conventional systemic therapies for MM. Among those receiving systemic therapy, monotherapy was the most common approach. Sites of metastases and physician speciality influenced treatment patterns. This study serves as a baseline against which future treatment pattern studies, following approval of new agents, can be compared. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/371326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32387173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy. 局部晚期和无法切除的皮肤鳞状细胞癌：同时使用西妥昔单抗和放疗的疗效。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-07-21 DOI: 10.1155/2014/284582

Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker

{"title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy.","authors":"Robert M Samstein, Alan L Ho, Nancy Y Lee, Christopher A Barker","doi":"10.1155/2014/284582","DOIUrl":"10.1155/2014/284582","url":null,"abstract":"Background. Advanced age and immune dysfunction are risk factors for cutaneous squamous cell carcinoma (cSCC) and often render patients with locally-advanced disease medically inoperable or surgically unresectable, but potentially curable with radiotherapy. Concurrent chemotherapy and radiotherapy may not be well tolerated in this population, but another systemic therapy may improve disease control. Objective. Determine the tolerance and efficacy of concurrent cetuximab and radiotherapy (CRT) for patients with locally advanced and unresectable cSCC. Methods. Retrospective analysis of 12 patients treated with CRT for locally advanced and unresectable cSCC. Results. Patients were elderly and 75% had moderate-to-severe comorbidities, while 42% had immune dysfunction. Grades 3-4 adverse events were noted in 83% of patients; 67% required hospital admission for adverse events. Complete and partial response was noted in 36% and 27% (response rate, 64%). Stable and progressive disease was noted in 3 and 1 patients, respectively (disease control rate, 91%). Median progression-free and overall survival were 6.4 and 8.0 months, respectively. Limitations. Retrospective small-cohort, single-institution analysis. Conclusion. Patients selected for CRT were elderly, with comorbidities and immune dysfunction, but treatment responses were observed. Patients selected for this treatment approach have a poor prognosis with limited capacity for therapy; more effective treatment is needed. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32596866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the definitions of "high-risk" cutaneous squamous cell carcinoma using the american joint committee on cancer staging criteria and national comprehensive cancer network guidelines. 使用美国癌症分期标准联合委员会和国家综合癌症网络指南评估“高风险”皮肤鳞状细胞癌的定义。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-09-17 DOI: 10.1155/2014/154340

Melinda B Chu, Jordan B Slutsky, Maulik M Dhandha, Brandon T Beal, Eric S Armbrecht, Ronald J Walker, Mark A Varvares, Scott W Fosko

{"title":"Evaluation of the definitions of \"high-risk\" cutaneous squamous cell carcinoma using the american joint committee on cancer staging criteria and national comprehensive cancer network guidelines.","authors":"Melinda B Chu, Jordan B Slutsky, Maulik M Dhandha, Brandon T Beal, Eric S Armbrecht, Ronald J Walker, Mark A Varvares, Scott W Fosko","doi":"10.1155/2014/154340","DOIUrl":"https://doi.org/10.1155/2014/154340","url":null,"abstract":"Recent guidelines from the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) have been proposed for the assessment of \"high-risk\" cutaneous squamous cell carcinomas (cSCCs). Though different in perspective, both guidelines share the common goals of trying to identify \"high-risk\" cSCCs and improving patient outcomes. Thus, in theory, both definitions should identify a similar proportion of \"high-risk\" tumors. We sought to evaluate the AJCC and NCCN definitions of \"high-risk\" cSCCs and to assess their concordance. Methods. A retrospective review of head and neck cSCCs seen by an academic dermatology department from July 2010 to November 2011 was performed. Results. By AJCC criteria, most tumors (n = 211,82.1%) were of Stage 1; 46 tumors (13.9%) were of Stage 2. Almost all were of Stage 2 due to size alone (≥2 cm); one tumor was \"upstaged\" due to \"high-risk features.\" Using the NCCN taxonomy, 231 (87%) of tumors were \"high-risk.\" Discussion. This analysis demonstrates discordance between AJCC and NCCN definitions of \"high-risk\" cSCC. Few cSCCs are of Stage 2 by AJCC criteria, while most are \"high-risk\" by the NCCN guidelines. While the current guidelines represent significant progress, further studies are needed to generate a unified definition of \"high-risk\" cSCC to optimize management. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/154340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32741600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 40

A study of Basal cell carcinoma in South asians for risk factor and clinicopathological characterization: a hospital based study. 南亚基底细胞癌的危险因素和临床病理特征研究:一项基于医院的研究。

IF 1.1

Journal of Skin Cancer Pub Date : 2014-01-01 Epub Date: 2014-11-03 DOI: 10.1155/2014/173582

Sumir Kumar, Bharat Bhushan Mahajan, Sandeep Kaur, Ashish Yadav, Navtej Singh, Amarbir Singh

{"title":"A study of Basal cell carcinoma in South asians for risk factor and clinicopathological characterization: a hospital based study.","authors":"Sumir Kumar, Bharat Bhushan Mahajan, Sandeep Kaur, Ashish Yadav, Navtej Singh, Amarbir Singh","doi":"10.1155/2014/173582","DOIUrl":"https://doi.org/10.1155/2014/173582","url":null,"abstract":"Objectives. Although the incidence of skin cancers in India (part of South Asia) is low, the absolute number of cases may be significant due to large population. The existing literature on BCC in India is scant. So, this study was done focusing on its epidemiology, risk factors, and clinicopathological aspects. Methods. A hospital based cross-sectional study was conducted in Punjab, North India, from 2011 to 2013. History, examination and histopathological confirmation were done in all the patients visiting skin department with suspected lesions. Results. Out of 36 confirmed cases, 63.9% were females with mean ± SD age being 60.9 ± 14.2 years. Mean duration of disease was 4.7 years. Though there was statistically significant higher sun exposure in males compared to females (P value being 0.000), BCC was commoner in females, explainable by intermittent sun exposure (during household work in the open kitchens) in women. Majority of patients (88.9%) had a single lesion. Head and neck region was involved in 97.2% of cases, with nose being the commonest site (50%) with nodular/noduloulcerative morphology in 77.8% of cases. Pigmentation was evident in 22.2% of cases clinically. Nodular variety was the commonest histopathological variant (77.8%). Conclusions. This study highlights a paradoxically increasing trend of BCC with female preponderance, preferential involvement of nose, and higher percentage of pigmentation in Indians. ","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/173582","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32927533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 35